Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of$ 0.87. This compares to loss of $1.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this company would post a loss of$ 1.07 per share when it actually produced a loss of $0.79, delivering a surprise of 26.17%. Over the last four quarters, the compa ...